Lumachi F, Brandes A A, Boccagni P, Polistina F, Favia G, D'Amico D F
Dept. of Surgical and Gastroenterologic Sciences, University of Padua, School of Medicine, Italy.
Anticancer Res. 1999 Sep-Oct;19(5C):4485-9.
The aim of this study was to evaluate CEA and CA 15-3 changes in patients surgically treated for breast cancer. One hundred and three women (median age 59 years, range 31-83 years) with pT1-2, pN0-1, M0 breast cancer were followed up for at least 5 years. CEA and CA 15-3 serum levels were measured before operation and every 6 months during follow-up. The diagnostic sensitivity of CEA and CA 15-3 was 22.3% and 33.3% respectively. There was a significant difference (p < 0.01) between pre- and post-operative (6 months and 5 years after surgery) mean CEA serum levels independent of TNM staging. During follow-up, 21 (20.4%) patients showed recurrence of cancer and overall CEA and CA 15-3 sensitivity was 38.1% and 61.1%, with 98.8% and 91.2% specificity, respectively. Tumor marker measurement may be useful in post-surgical follow-up, but at present they are neither sensitive nor specific enough for early diagnosis of malignancy.
本研究的目的是评估接受乳腺癌手术治疗患者的癌胚抗原（CEA）和糖类抗原15-3（CA 15-3）的变化情况。103例pT1-2、pN0-1、M0期乳腺癌女性患者（年龄中位数59岁，范围31 - 83岁）接受了至少5年的随访。术前及随访期间每6个月检测CEA和CA 15-3血清水平。CEA和CA 15-3的诊断敏感性分别为22.3%和33.3%。无论TNM分期如何，术前与术后（术后6个月和5年）CEA血清平均水平存在显著差异（p < 0.01）。随访期间，21例（20.4%）患者出现癌症复发，CEA和CA 15-3的总体敏感性分别为38.1%和61.1%，特异性分别为98.8%和91.2%。肿瘤标志物检测在术后随访中可能有用，但目前它们对恶性肿瘤的早期诊断既不敏感也不够特异。
